- Home
- SOHU vs CLLS Comparison
SOHU vs CLLS Comparison
Compare SOHU & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOHU | CLLS |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 394.4M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SOHU | CLLS |
|---|---|---|
| Price | $12.83 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.00 | $8.33 |
| AVG Volume (30 Days) | 61.1K | ★ 155.9K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | $0.98 |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $1.25 |
| 52 Week High | $17.30 | $5.48 |
Technical Indicators
Market Signals| Indicator | SOHU | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 22.61 |
| Support Level | $11.61 | N/A |
| Resistance Level | $13.71 | $3.47 |
| Average True Range (ATR) | 0.49 | 0.21 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 21.92 | 11.57 |
Price Performance
Historical ComparisonAbout SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.